These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 16100648

  • 1. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B, Uzaslan E, Budak F, Karadağ M, Ediger D, Oral B, Göral G, Ege E, Gözü O.
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [Abstract] [Full Text] [Related]

  • 2. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL.
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
    Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H.
    Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis.
    Lee KS, Choi YH, Kim YS, Baik SH, Oh YJ, Sheen SS, Park JH, Hwang SC, Park KJ.
    Respir Med; 2008 Mar; 102(3):464-9. PubMed ID: 17988850
    [Abstract] [Full Text] [Related]

  • 11. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H, Narita K, Endo S.
    J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T, Toi M, Tominaga T.
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
    Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J.
    Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C, Maurel J, Gallego R, Castells A, Longarón R, Marmol M, Sanz S, Molina R, Martin-Richard M, Gascón P.
    Clin Cancer Res; 2005 Jul 01; 11(13):4770-4. PubMed ID: 16000573
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Measurement of soluble Fas antigen and ligand in circulating serum and intra-abdominal or cerebrospinal fluid during gastrointestinal or cerebrovascular surgery.
    Iwama H, Kato M, Ohmori S, Akimaru K, Tsutsumi K, Tohma J, Nakamura N.
    J Crit Care; 2000 Sep 01; 15(3):119-25. PubMed ID: 11011825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.